ATE478059T1 - Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten - Google Patents

Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten

Info

Publication number
ATE478059T1
ATE478059T1 AT07786761T AT07786761T ATE478059T1 AT E478059 T1 ATE478059 T1 AT E478059T1 AT 07786761 T AT07786761 T AT 07786761T AT 07786761 T AT07786761 T AT 07786761T AT E478059 T1 ATE478059 T1 AT E478059T1
Authority
AT
Austria
Prior art keywords
cinnamoylpiperazine
par
antagonists
derivatives
cinnamoylpiperazine derivatives
Prior art date
Application number
AT07786761T
Other languages
English (en)
Inventor
Michel Perez
Marie Lamothe
Grand Bruno Le
Robert Letienne
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of ATE478059T1 publication Critical patent/ATE478059T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
AT07786761T 2006-06-19 2007-06-19 Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten ATE478059T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605419A FR2902426B1 (fr) 2006-06-19 2006-06-19 Derives de cinnamoyl-piperazine
PCT/EP2007/056086 WO2007147824A1 (en) 2006-06-19 2007-06-19 Cinnamoyl-piperazine derivatives and their use as par- i antagonists

Publications (1)

Publication Number Publication Date
ATE478059T1 true ATE478059T1 (de) 2010-09-15

Family

ID=37846050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07786761T ATE478059T1 (de) 2006-06-19 2007-06-19 Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten

Country Status (32)

Country Link
US (2) US8217046B2 (de)
EP (1) EP2041104B1 (de)
JP (1) JP5356222B2 (de)
KR (1) KR101468752B1 (de)
CN (1) CN101472907B (de)
AR (1) AR061520A1 (de)
AT (1) ATE478059T1 (de)
AU (1) AU2007263051B2 (de)
BR (1) BRPI0713132B8 (de)
CA (1) CA2655527C (de)
CR (1) CR10509A (de)
DE (1) DE602007008572D1 (de)
EC (1) ECSP099065A (de)
ES (1) ES2349324T3 (de)
FR (1) FR2902426B1 (de)
GE (1) GEP20115201B (de)
HK (1) HK1127353A1 (de)
IL (1) IL195972A (de)
MA (1) MA30756B1 (de)
MX (1) MX2008016447A (de)
MY (1) MY144461A (de)
NO (1) NO341389B1 (de)
NZ (1) NZ573764A (de)
PL (1) PL2041104T3 (de)
PT (1) PT2041104E (de)
RU (1) RU2440997C2 (de)
SA (1) SA07280330B1 (de)
TN (1) TNSN08522A1 (de)
TW (1) TWI404710B (de)
UA (1) UA96947C2 (de)
WO (1) WO2007147824A1 (de)
ZA (1) ZA200900303B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3014693B1 (fr) * 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015173802A1 (en) 2014-05-11 2015-11-19 Tel Hashomer Medical Research Infrastructure And Services Ltd. Par-1 based therapeutic conjugates and uses thereof
WO2016066789A1 (fr) * 2014-10-31 2016-05-06 Pierre Fabre Medicament Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
CN104496924B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 卤苯二烯四氮唑类化合物、其制备方法和用途
CN104496922B (zh) * 2015-01-13 2016-04-06 佛山市赛维斯医药科技有限公司 腈基苯二烯四氮唑类化合物、其制备方法和用途
CN104529860B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含硝基苯和二烯氟代金刚烷结构的化合物及制备方法
CN104496879A (zh) * 2015-01-13 2015-04-08 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯氟代金刚烷结构的化合物和用途
CN105949116A (zh) * 2016-06-08 2016-09-21 青岛理工大学 酰基哌嗪类化合物及其制备方法和用途
EP3278802A1 (de) 2016-08-04 2018-02-07 Metabolys Neue behandlung für nichtalkoholische steatohepatitis und fibrose
RU2662308C1 (ru) * 2017-12-25 2018-07-25 Феркат Адельзянович Халиуллин Средство для лечения и профилактики тромбоза
US11497793B2 (en) 2018-05-02 2022-11-15 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating glioblastoma
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
KR20230046343A (ko) * 2021-09-29 2023-04-06 주성수 피페론구민계 화합물을 유효성분으로 포함하는 혈관질환 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61106564A (ja) * 1984-10-30 1986-05-24 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO2002076965A1 (en) * 2001-03-23 2002-10-03 John Matsoukas Non peptide mimetics based on the active sequence s42fllr46 of the thrombin receptor for the treatment of thrombosis and cancer
CN1775762A (zh) * 2005-12-06 2006-05-24 山东大学 川芎嗪酰基哌嗪衍生物、制备方法和药物组合物与应用
FR2917622B1 (fr) * 2007-06-19 2009-10-23 Pierre Fabre Medicament Sa Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Also Published As

Publication number Publication date
DE602007008572D1 (de) 2010-09-30
BRPI0713132A2 (pt) 2012-04-17
IL195972A0 (en) 2009-09-01
MA30756B1 (fr) 2009-10-01
TNSN08522A1 (en) 2010-04-14
CA2655527C (en) 2014-12-23
CN101472907A (zh) 2009-07-01
KR20090031572A (ko) 2009-03-26
HK1127353A1 (en) 2009-09-25
NO20090270L (no) 2009-03-03
US20090176803A1 (en) 2009-07-09
FR2902426B1 (fr) 2008-09-05
SA07280330B1 (ar) 2010-10-23
UA96947C2 (ru) 2011-12-26
TWI404710B (zh) 2013-08-11
RU2440997C2 (ru) 2012-01-27
BRPI0713132B1 (pt) 2020-10-20
GEP20115201B (en) 2011-04-11
ECSP099065A (es) 2009-02-27
ES2349324T3 (es) 2010-12-30
CN101472907B (zh) 2012-08-29
AU2007263051B2 (en) 2011-10-20
ZA200900303B (en) 2009-12-30
JP5356222B2 (ja) 2013-12-04
BRPI0713132B8 (pt) 2021-05-25
NZ573764A (en) 2011-01-28
AU2007263051A1 (en) 2007-12-27
CA2655527A1 (en) 2007-12-27
PT2041104E (pt) 2010-11-08
MY144461A (en) 2011-09-30
US8513258B2 (en) 2013-08-20
MX2008016447A (es) 2009-01-22
JP2009541260A (ja) 2009-11-26
TW200808742A (en) 2008-02-16
US20120232097A1 (en) 2012-09-13
PL2041104T3 (pl) 2011-01-31
IL195972A (en) 2014-05-28
CR10509A (es) 2009-02-05
KR101468752B1 (ko) 2014-12-03
EP2041104B1 (de) 2010-08-18
FR2902426A1 (fr) 2007-12-21
NO341389B1 (no) 2017-10-30
WO2007147824A1 (en) 2007-12-27
EP2041104A1 (de) 2009-04-01
US8217046B2 (en) 2012-07-10
AR061520A1 (es) 2008-09-03
RU2008152247A (ru) 2010-07-27

Similar Documents

Publication Publication Date Title
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
DE602007013869D1 (de) Substituierte imidazole und ihre verwendung als pestizide
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
ATE520681T1 (de) N-thioanthranilamidverbindungen und ihre verwendung als pestizide
ATE546433T1 (de) Quinolinderivate und ihre verwendung als fungizide
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
ATE548355T1 (de) 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE473214T1 (de) 2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
ATE512966T1 (de) Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
ATE440093T1 (de) 1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
DE602007013295D1 (de) Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
ATE440095T1 (de) Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist
ATE514695T1 (de) Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
ATE470667T1 (de) Neue benzothiazinonderivate und ihre verwendung als antibakterielle mittel
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE538130T1 (de) Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE417045T1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
ATE547002T1 (de) Pestizide und ihre verwendung
ATE544752T1 (de) Aryloxyacetamidderivate und ihre verwendung als fungizide
ATE442366T1 (de) Oxazolidinonderivate und ihre verwendung als antibiotika

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties